Polycystic Ovary Syndrome (PCOS) Treatment Market Synopsis:
\nPolycystic Ovary Syndrome (PCOS) Treatment Market Size Was Valued at USD 4.53 Billion in 2023, and is Projected to Reach USD 7.68 Billion by 2032, Growing at a CAGR of 6.5% From 2024-2032.
\nPolycystic Ovary Syndrome (PCOS) is an endocrine disorder which affects women of child-bearing age, and is manifested with hormonal disturbances, menstrual irregularities and ovarian cysts. PCOS treatment can be a list of therapeutic strategies for the treatment of this predominantly estrogen-dependent illness including pharmacological therapy compose of oral contraceptives, insulin-sensitizing agents and anti-androgens and non-pharmacological including lifestyle changes.<\/p>\n
Global PCOS treatment market has been growing at a faster pace in the recent past, mainly due to a growing awareness of the condition and its impact on the global female population. The market was estimated at nearly USD 4.53 billion in 2023 and is expected to achieve CAGR of 6.5% for the duration from 2024 to 2030. This rise can be ascribed to factors including modification of life styles, high stress levels, obesity and diabetes which are risk factors for development of PCOS. Also, a rise in the quality of diagnostic methods and a shift of focus more towards women operating in the market has created the market.<\/p>\n
North America and Europe are the largest markets for PCOS treatment because a majority of these regions have established healthcare facilities, better health awareness, and access to superior treatment. In 2023, North America is expected to take a large stake worldwide while the United States market is likely to reach USD 820.5 million. However, it is estimated that Asia Pacific will experience the highest level of growth in the forecast period with country such as China expected to grow at a CAGR of 6.4 % within the period between 2023 to 2030. Such a rapid growth is due to the growing concerns regarding health, especially in women, elevating incidence of PCOS, and enhancement of healthcare infrastructure in the area.<\/p>\n
Polycystic Ovary Syndrome (PCOS) Treatment Market Trend Analysis:
\nEmerging Trends in PCOS Treatment<\/p>\n
Another key observation made for the PCOS treatment market is the trend towards further individualization of medicine and creation of tailored therapies. Scientists and drug makers are paying attention to possible genetic and molecular origins of PCOS in the hopes of catering treatment that addresses the roots of the disease not just its symptoms. The concept behind it is focused on enhancing the patient care to more precise and personal, therefore success rates and patients\u2019 quality of life will increase. <\/p>\n
Also, there has been a progressive concern for non-drug management or policy of PCOS which includes dietary changes and other complementary therapeutics treatments.
\nOpportunities in the PCOS Treatment Market<\/p>\n
Many patients worldwide suffer from PCOS and increases continually; thus, market players have a vast array of opportunities to thrive. Therefore, there is a large market opportunity for safe and efficacious interventions, especially in low-income and middle-income countries with low health literacy and limited access to healthcare services. Finding effective and unique treatments, and focusing on the promotion and increasing the rate of diagnosing affected people can help companies benefit from such markets. <\/p>\n
In addition, partnerships for total control approaches within the healthcare sector and with policy-makers should also be developed to advance market development.
\nPolycystic Ovary Syndrome (PCOS) Treatment Market Segment Analysis:
\nPolycystic Ovary Syndrome (PCOS) Treatment Market Segmented based on drug class, surgery and region.
\nBy Drug Class, Oral Contraceptives Segment is Expected to Dominate the Market During the Forecast Period<\/p>\n
As for the Polycystic Ovary Syndrome (PCOS) treatment map is divided based on the drug class, the top selling treatment for the ailment happens to be oral contraceptives. These meds act to help normalise menstrual cycles in female patients, control the levels of androgens, and control acne and hirsutism for example. Other drugs like metformin, which belong to the insulin-sensitizing drugs class, may also be recommended to decongest insulin resistance, which is often the root of all problems in PCOS. These drugs are very useful in regulation of blood glucose and prevention of the diabetes type 2 in patients with PCOS.<\/p>\n
The other major class of drugs which can be utilized are antiandrogens, which act opposite to androgens and contain symptoms such as hirsutism and hair loss. Furthermore, another cause of medication used in the treatment of PCOS is antidepressants, which are mostly used because Psychosocial disorders like anxiety and depression are common in women with PCOS. Some of the Common pharmacological treatments include aromatase inhibitors, selective estrogen receptor modulators (SERMs); diuretic therapies including spironolactone tone in the treatment of infertility PCOS. There is a need to reassure women with PCOS the variety of drugs that can be used because this is a disease with so many symptoms that needs a complex approach.
\nBy Surgery, Laparoscopic Ovarian Drilling Segment Expected to Held the Largest Share <\/p>\n
LOD is an effective procedure for the treatment of PCOS women with prior failure to respond to ovulation inducing drugs. The procedure involves the insertion of a laparoscope to see the ovaries; then, a hole is then made in the ovary surface with other special equipment. This assists to decrease levels of androgen and bring balance to the ovulation process making it a suitable treatment to fertility problems caused by PCOS. LOD is non-invasive and is sometimes done when all the other treatments make very little or no impact.<\/p>\n
Although observational studies have shown that laparoscopic ovarian drilling promote fertility, its effects come with some risks like formation of ovarian adhesions and low ovarian reserve. It also revealed that patient characteristics, such as age and grade of PCOS, influence the effectiveness of the procedure. Nonetheless, LOD still has a role in the management of well-selected candidates after having the knowledge that the procedure is an option for women with infertility due to PCOS.
\nPolycystic Ovary Syndrome (PCOS) Treatment Market Regional Insights:
\nNorth America is Expected to Dominate the Market Over the Forecast period <\/p>\n
Taking 2023 as the base year, the North America market for Polycystic Ovary Syndrome (PCOS) treatment was found to be leading the market, while the market size of the U.S. was found to be around USD 820.5 million. The reasons for this can be linked to elevated rates of PCOS within females within the region, enhanced access to health care that enables early signs to be recognized and treated. Programs aimed at raising awareness of women\u2019s health have helped many females learn about PCOS and prompted them to receive treatment, propelling the market ahead.<\/p>\n
Also, to the advantage of North American nations, there is a strong commitment to research and development and this is being driven by major pharmaceutical industries based in the region. New treatments and therapies have been made available by these companies thus providing depth to this market. With a strategic vision towards the control and management of PCOS, leveraging medical innovation, governmental support and public awareness, the region has cemented its position as the leaders in controlling the PCOS market.
\nActive Key Players in the Polycystic Ovary Syndrome (PCOS) Treatment Market:<\/p>\n
Abbott Laboratories (USA)<\/p>\n
Agile Therapeutics, Inc. (USA)<\/p>\n
Bayer AG (Germany)<\/p>\n
Bristol Myers Squibb Co. (USA)<\/p>\n
Cadila Pharmaceuticals Ltd. (India)<\/p>\n
Crinetics Pharmaceuticals, Inc. (USA)<\/p>\n
Eli Lilly and Company (USA)<\/p>\n
Ferring Pharmaceuticals Inc. (Switzerland)<\/p>\n
GlaxoSmithKline PLC (UK)<\/p>\n
Glenmark Pharmaceuticals Inc. (India)<\/p>\n
Italfarmaco SpA (Italy)<\/p>\n
Lupin Ltd. (India)<\/p>\n
Merck & Co., Inc. (USA)<\/p>\n
Novartis AG (Switzerland)<\/p>\n
Sanofi (France), and Other active Players
\nKey Industry Developments of Global Polycystic Ovary Syndrome (PCOS) Treatment Market:<\/p>\n
In August 2024, continuing in its major efforts to transform PCOS care and empower stakeholders, PCOS Challenge: The National Polycystic Ovary Syndrome Association organized the largest PCOS Awareness Month for this September with nearly 1,000 partners and over 400 lighting events in 33 countries. “Voice of Strength, Agents of Change” is the 2024 PCOS Awareness Month theme. The September events and campaign are set to galvanize patients, healthcare providers, researchers, policymakers, and industry leaders to join forces in addressing the urgent needs of the PCOS community.<\/p>\n
In May 2024, May Health, a clinical-stage medical device company dedicated to helping those living with the endocrine disorder polycystic ovary syndrome (PCOS), today announced it has closed a $25 million Series B financing round, co-led by Bpifrance and Trill Impact with participation from founding investor Sofinnova Partners, Avestria Ventures, and Kidron Capital Assets LP. Funds will be used to support the company\u2019s growth and advance its Ovarian Rebalancing\u2122 therapy through the pivotal REBALANCE Study, evaluating its potential to address PCOS-related infertility.<\/p>\n","protected":false},"excerpt":{"rendered":"
Polycystic Ovary Syndrome (PCOS) is an endocrine disorder which affects women of child-bearing age, and is manifested with hormonal disturbances, menstrual irregularities and ovarian cysts. PCOS treatment can be a list of therapeutic strategies for the treatment of this predominantly estrogen-dependent illness including pharmacological therapy compose of oral contraceptives, insulin-sensitizing agents and anti-androgens and non-pharmacological including lifestyle changes.<\/p>\n","protected":false},"featured_media":23136,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[194],"product_tag":[],"class_list":["post-25945","product","type-product","status-publish","has-post-thumbnail","product_cat-healthcare-life-sciences","first","instock","virtual","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n